Xuan Jiang
No. 253, Gongye Middle Avenue, Haizhu District
Guangzhou, 510280, China
Guangzhou, 510280, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Adipose-derived mesenchymal stem cell exosomes enhance diabetic wound healing via the amelioration of fibroblast senescence through the SMARCAL1-Drp1 signaling pathway.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: September 19, 2025
Safety and Efficacy of Micronized Acellular Dermal Matrix Injection for Correction of Moderate to Severe Nasolabial Folds: A Double-Blind, Multicenter, Randomized Controlled, Non-inferior Clinical Trial.
Journal: Aesthetic plastic surgery
Published: June 16, 2025
Prophylactic effect of the traditional Chinese medicine formula danxiong granules (TDX105) on hand-foot skin reaction associated with the antitumor targeted drug regorafenib: a randomized, double-blind, placebo-controlled trial.
Journal: Frontiers in pharmacology
Published: June 12, 2025
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma.
Journal: Future oncology (London, England)
Published: December 18, 2024
The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Journal: Frontiers in immunology
Published: November 28, 2022
Increased PD-1+Foxp3+ γδ T cells associate with poor overall survival for patients with acute myeloid leukemia.
Journal: Frontiers in oncology
Published: October 17, 2022
Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Journal: Frontiers in pharmacology
Published: January 09, 2022
TIGIT axis: novel immune checkpoints in anti-leukemia immunity.
Journal: Clinical and experimental medicine
Published: December 07, 2021
High TRGV 9 Subfamily Expression Marks an Improved Overall Survival in Patients With Acute Myeloid Leukemia.
Journal: Frontiers in immunology
Published: November 27, 2021
First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
Journal: Cancer immunology, immunotherapy : CII
Published: August 09, 2021
Last Updated: 09/26/2026